|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of Klf4 in the nucleus can be used as a biomarker for predicting the effects of cetuximab treatment in nasopharyngeal carcinoma, which might be attributed to the H-RAS and PI3K mutations, leading to cetuximab resistance.
|
29973197 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, TCS radiosensitized NPC <i>in vitro</i> and <i>in vivo</i> via downregulation of PI3K pathways and the upregulation of cleaved caspase-3.
|
30402158 |
2018 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
STYK1 promotes Warburg effect through PI3K/AKT signaling and predicts a poor prognosis in nasopharyngeal carcinoma.
|
28720063 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, DAB2IP suppresses growth and metastasis of NPC probably by targeting PI3K/Akt pathway, and may act as a hopeful therapeutic target for NPC.
|
28586035 |
2017 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that PI3K/AKT pathway has an important role in the induction and maintenance of CSC properties in NPC.
|
26568302 |
2016 |
|
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
|
27876891 |
2016 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study suggests that PI3K p110α overexpression, which is attributed, at least in part, to PIK3CA gene amplification, may contribute to NPC pathogenesis.
|
26581613 |
2016 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The current study demonstrated that EphA2 mediates sensitivity to paclitaxel via the regulation of the PI3K/Akt signalling pathway in NPC.
|
25351620 |
2015 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, restoration of INPP4B expression significantly suppressed PI3K/AKT downstream signals in the NPC C666-1 cells.
|
25126743 |
2014 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.
|
24041865 |
2014 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our studies are the first to demonstrate that reduced CTGF as an unfavorable prognosis factor mediates the activation of miR-18b, an oncomir directly suppresses CTGF expression, by PI3K/AKT/C-Jun and C-Myc and promotes cell growth of NPC.
|
23681229 |
2013 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It may also contribute to the development of new therapeutic strategies to block the PI3K/AKT pathway in NPC cancer cells.
|
20927779 |
2010 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is important in nasopharyngeal carcinoma (NPC) pathogenesis.
|
19276680 |
2009 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings show that mutated PI3K may be involved in the NPC tumorigenesis but does not affect patient's prognosis, suggesting that PI3K is a potential target in NPC for targeted therapeutics using specific kinase inhibitors.
|
19012001 |
2009 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data revealed that the EGFR/PI3K/Akt signaling pathway is important in NPC pathogenesis and that PIK3CA hotspot mutations are rare in NPC.
|
18202777 |
2008 |
|
Nasopharyngeal carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK.
|
18789327 |
2008 |
|
Nasopharyngeal carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, BMI-1 depletion enhanced the chemosensitivity of NPC cells by inducing apoptosis; which is associated with inhibition of the PI3K/AKT pathway.
|
18452707 |
2008 |